---
title: "This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295820138.md"
description: "On Thursday, Omeros stock reached a peak not seen in five years following exceptional second-quarter results for its latest treatment addressing transplant complications. The surge in stock value is attributed to the successful performance of the new treatment in the market."
datetime: "2026-08-13T15:10:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295820138.md)
  - [en](https://longbridge.com/en/news/295820138.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295820138.md)
---

# This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

On Thursday, Omeros stock reached a peak not seen in five years following exceptional second-quarter results for its latest treatment addressing transplant complications. The surge in stock value is attributed to the successful performance of the new treatment in the market.

### Related Stocks

- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)

## Related News & Research

- [Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/295993093.md)
- [Omeros director Joseph L. Schocken files initial beneficial ownership statement](https://longbridge.com/en/news/296288452.md)
- [Omeros VP Finance, CAO David J. Borges sells 5,000 shares worth $84,750](https://longbridge.com/en/news/296155281.md)
- [Omeros’ $100 Million Buyback Plan: How Discretionary Repurchases Could Distort Share Price and Heighten Volatility](https://longbridge.com/en/news/295898420.md)
- [Omeros appoints Tranceka Capital founder Joseph Schocken to board](https://longbridge.com/en/news/295840571.md)